Skip to main content
SpringerLink
Log in

Epidemiology and Risk Factors of Drug-Induced Lung Disease: What Are the Prevalence and Risk Factors of DILD?

  • Chapter
  • First Online:
Book cover Drug-Induced Lung Injury

  • 726 Accesses

Abstract

The precise frequency of drug-induced lung disease (DILD) is unclear, but the reported number of cases of DILD has been increasing, especially after reports of severe DILD caused by gefitinib in Japan. General risk factors for DILD include current smoking, old age, preexisting lung disease (especially interstitial pneumonia), history of thoracic surgery or irradiation of the lung, and renal failure. There are ethnic differences in the frequency of DILD caused by certain drugs, and genetic factors may partially contribute to this. In addition to classic antineoplastic agents, antirheumatic drugs, interferon, herbal medicine, and molecularly targeted drugs frequently cause DILD. Checkpoint inhibitors can also cause severe interstitial lung disease (ILD) as one of a variety of side effects associated with their immunomodulatory function.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Thomeer M, Demedts M, Vandeurzen K, VRGT Working Group on Interstitial Lung Diseases. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001;56:163–72.

    Article  CAS  PubMed  Google Scholar 

  2. King TE, Schwarz MI, editors. Interstitial lung disease. 5th ed. Shelton, CT: People’s Medical Publishing House; 2010. p. 637–88.

    Google Scholar 

  3. Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. JMAJ. 2007;50:405–11.

    Google Scholar 

  4. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, Dohi M, Tokuda H, Hashimoto S, Hattori N, Hanaoka M, Fukuda Y, Japanese Respiratory Society Committee for Formulation of Consensus Statement for the Diagnosis and Treatment of Drug-Induced Lung Injuries. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51:260–77.

    Article  PubMed  Google Scholar 

  5. Pharmaceutical and Medical Device Agency. http://www.info.pmda.go.jp/. Accessed 07 Aug 2016.

  6. Shiihara J, Inoue Y, Miyazawa H, Ohta H, Hagiwara K. MUC4 variants in patients with EGFR-TKI-induced interstitial lung disease and its detection assay. In: The 55th annual meeting of Japan lung cancer society, Kyoto; 2014.

    Google Scholar 

  7. O’Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91.

    Article  PubMed  Google Scholar 

  8. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med. 1990;11:1–20.

    CAS  PubMed  Google Scholar 

  9. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614.

    Article  CAS  PubMed  Google Scholar 

  10. Blum RH, Carter SK, Agre K. A clinical review of bleomycin–a new antineoplastic agent. Cancer. 1973;31:903–14.

    Article  CAS  PubMed  Google Scholar 

  11. Beynat-Mouterde C, Beltramo G, Lezmi G, Pernet D, Camus C, Fanton A, Foucher P, Cottin V, Bonniaud P. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J. 2014;44:523–7.

    Article  PubMed  Google Scholar 

  12. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8:303–6.

    Article  CAS  PubMed  Google Scholar 

  13. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177:1348–57.

    Article  PubMed  Google Scholar 

  14. Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:5080–7.

    Article  CAS  PubMed  Google Scholar 

  15. Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010;5:1616–22.

    Article  PubMed  Google Scholar 

  16. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–9.

    Article  CAS  PubMed  Google Scholar 

  17. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367–73.

    Article  CAS  PubMed  Google Scholar 

  18. Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, et al. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol. 2013;18:743–9.

    Article  CAS  PubMed  Google Scholar 

  19. Herceptin (trastuzumab). US National Library of Medicine. www.dailymed.nlm.nih.gov. Accessed 03 Aug 2016.

  20. Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M, Cadranel J. Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review. J Thorac Oncol. 2015;10:1148–55.

    Article  PubMed  Google Scholar 

  21. Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer. 2012;48:1519–24.

    Article  CAS  PubMed  Google Scholar 

  22. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–18.

    Article  CAS  PubMed  Google Scholar 

  23. Atkinson BJ, Cauley DH, Ng C, et al. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. 2014;113:376–82.

    Article  CAS  PubMed  Google Scholar 

  24. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010;182:396–403.

    Article  PubMed  Google Scholar 

  25. Gettinger SN, Zhang X, Homer R, Possick J, Wurtz A, Goldberg SB, Chiang AC, Herbst RS, Rubinowitz A, Yale Comprehensive Cancer Center, New Haven, CT. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. J Clin Oncol. 2016;35(7):709–17.

    Google Scholar 

  26. Berthod G, Lazor R, Letovanec I, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30:e156–9.

    Article  PubMed  Google Scholar 

  27. Barjaktarevic IZ, Qadir N, Suri A, et al. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest. 2013;143:858–61.

    Article  PubMed  Google Scholar 

  28. Ahn MJ, Yang J, Yu H, Saka H, Ramalingam S, Goto K, Kim SW, Yang L, Walding A, Oxnard GR. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol. 2016;11(4 Suppl):S115.

    Article  PubMed  Google Scholar 

  29. Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45:787–9.

    Article  CAS  Google Scholar 

  30. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356–64.

    Article  PubMed  Google Scholar 

  31. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004;50:1370–82.

    Article  CAS  PubMed  Google Scholar 

  32. Ito S, Sumida T. Interstitial lung disease associated with leflunomide. Intern Med. 2004;43:1103–4.

    Article  PubMed  Google Scholar 

  33. Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, Matsuda T, Takemura T, Sagawa A, Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1069–72.

    Article  CAS  Google Scholar 

  34. Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci. 2010;55:579–85.

    Article  CAS  PubMed  Google Scholar 

  35. Jackevicius CA, Tom A, Essebag V, et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol. 2011;108:705–10.

    Article  CAS  PubMed  Google Scholar 

  36. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 1990;82:51–9.

    Article  CAS  PubMed  Google Scholar 

  37. Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J. 2007;71:1610.

    Article  CAS  PubMed  Google Scholar 

  38. Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol. 2008;66:82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kyoto University Hospital, 54 Kawaharacho Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

    Tomohiro Handa & Atsushi Yonezawa

  2. Nippon Medical School, 1-1-5 Sendagi, Bunkyo, Tokyo, 113-8603, Japan

    Arata Azuma

Authors
  1. Tomohiro Handa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsushi Yonezawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arata Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arata Azuma .

Editor information

Editors and Affiliations

  1. First Department of Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan

    Masayuki Hanaoka

  2. Ibaraki Medical Center, Tokyo Medical University, Ibaraki, Japan

    Hiroyuki Nakamura

  3. Ibaraki Medical Center, Tokyo Medical University, Ibaraki, Japan

    Kazutetsu Aoshiba

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Handa, T., Yonezawa, A., Azuma, A. (2018). Epidemiology and Risk Factors of Drug-Induced Lung Disease: What Are the Prevalence and Risk Factors of DILD?. In: Hanaoka, M., Nakamura, H., Aoshiba, K. (eds) Drug-Induced Lung Injury. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-10-4466-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-4466-3_2

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-4465-6

  • Online ISBN: 978-981-10-4466-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation